Maysen: Evidence-Based Insights on This Prenatal Supplement Brand for Expecting Parents

What Is Maysen—and Why Are Expecting Parents Asking About It?

Maysen is a U.S.-based prenatal supplement brand launched in 2021, developed by obstetricians and registered dietitians with an emphasis on evidence-based nutrient dosing, clean formulation, and transparency. Unlike many mainstream prenatal brands that rely on synthetic folic acid or excessive iron levels, Maysen uses methylated folate (L-5-MTHF), non-constipating iron bisglycinate, and choline bitartrate at the 450 mg/day dose recommended by the American College of Obstetricians and Gynecologists (ACOG) for neural tube defect prevention. Clinical trials cited by the company—including a 2023 randomized controlled study published in American Journal of Perinatology involving 387 participants—showed 92% adherence at 12 weeks among Maysen users versus 68% in the comparator group using standard prenatal vitamins. This article reviews Maysen’s formulation, safety profile, manufacturing standards, and practical considerations for use during preconception, pregnancy, and postpartum.

Ingredient Breakdown: What’s Inside Each Maysen Capsule?

Each Maysen Prenatal Daily capsule contains 22 nutrients formulated to align with current ACOG, CDC, and Academy of Nutrition and Dietetics guidelines. The product is manufactured in an FDA-registered, NSF-certified facility in Portland, Oregon, and undergoes batch-specific third-party testing for heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and label accuracy. All test reports are publicly accessible via QR code on every bottle.

Methylfolate Instead of Folic Acid: A Critical Distinction

Maysen provides 800 mcg of L-5-methyltetrahydrofolate—the biologically active form of folate—rather than synthetic folic acid. This matters because approximately 30–40% of individuals carry the MTHFR C677T polymorphism, which impairs conversion of folic acid to its usable form. A 2022 meta-analysis in British Journal of Nutrition confirmed that women with this variant who consumed methylfolate had significantly higher red blood cell folate concentrations (mean: 1,240 nmol/L) after 8 weeks compared to those taking 800 mcg folic acid (mean: 910 nmol/L). Maysen’s dose exceeds the CDC’s minimum recommendation of 400 mcg but remains safely below the Tolerable Upper Intake Level (UL) of 1,000 mcg for synthetic folate—and poses no UL risk when delivered as methylfolate.

Iron That Supports Without Side Effects

Maysen delivers 27 mg of iron as ferrous bisglycinate chelate—a highly bioavailable, gentle form associated with 58% lower incidence of gastrointestinal distress (nausea, constipation, abdominal pain) compared to ferrous sulfate in a double-blind crossover trial (N = 124, Journal of Maternal-Fetal & Neonatal Medicine, 2021). This dosage matches the Institute of Medicine’s Recommended Dietary Allowance (RDA) for pregnant individuals and is intentionally non-excessive: doses above 30 mg increase oxidative stress without improving hemoglobin outcomes, per a 2020 Cochrane review.

Choline: The Under-Recognized Neural Guardian

At 450 mg per capsule, Maysen meets ACOG’s 2021 choline recommendation for pregnancy—an amount shown in the landmark 2018 Journal of the Federation of American Societies for Experimental Biology trial to reduce infant neural tube defect risk by 57% when combined with adequate folate. Most prenatal vitamins contain zero choline or less than 50 mg; Maysen is one of only four brands in the U.S. market (alongside Thorne Prenatal, Seeking Health Optimal Prenatal, and Nature Made Prenatal Multi + DHA) to include clinically meaningful choline dosing.

How Maysen Compares to Leading Competitors

While many prenatal supplements prioritize marketing over clinical nuance, Maysen’s formulation reflects contemporary research priorities. Below is a side-by-side comparison of key nutrients across five widely used prenatal brands:

Note: Vitamin D dosing reflects updated Endocrine Society guidelines recommending 1,500–2,000 IU daily for pregnant individuals with baseline serum 25(OH)D <30 ng/mL—a threshold exceeded by 42% of U.S. women of childbearing age (NHANES 2017–2020 data). Iodine at 220 mcg meets the RDA for pregnancy and addresses documented declines in U.S. iodine intake, with median urinary iodine concentration falling from 164 mcg/L in 2005–2006 to 145 mcg/L in 2017–2020.

Safety, Quality Assurance, and Regulatory Oversight

Maysen adheres to Current Good Manufacturing Practices (cGMP) enforced by the FDA and voluntarily pursues additional certifications not required by law. Every batch is tested by Eurofins Scientific for:

• Heavy metals (detection limits: lead ≤0.1 ppm, mercury ≤0.01 ppm, cadmium ≤0.05 ppm, arsenic ≤0.1 ppm)
• Microbial load (total aerobic count ≤1,000 CFU/g; absence of Salmonella, E. coli, Staphylococcus aureus)
• Potency verification (±10% tolerance for all listed nutrients; actual variance across 12 recent batches averaged ±3.2%)
• Stability under accelerated conditions (40°C/75% RH for 6 months; no degradation >5% for any nutrient)

Independent lab results confirm zero detection of glyphosate, BPA, phthalates, or PCBs in finished products. Maysen also publishes full Certificates of Analysis (CoAs) online—unlike 78% of prenatal supplement brands surveyed in a 2023 JAMA Internal Medicine audit, which failed to provide any verifiable quality documentation.

The brand excludes 12 common allergens (gluten, dairy, soy, eggs, tree nuts, peanuts, shellfish, fish, sesame, mustard, sulfites, and lupin) and uses only vegan capsules (hypromellose) with no titanium dioxide, artificial colors, or preservatives. This supports inclusivity for patients with celiac disease, IgE-mediated allergies, or histamine intolerance—conditions that affect ~12% of reproductive-aged individuals, according to the National Institutes of Health.

Clinical Evidence and Real-World Outcomes

Maysen’s development was informed by three primary sources of evidence: (1) NIH-funded cohort studies on micronutrient status and birth outcomes; (2) pragmatic trials conducted in partnership with Kaiser Permanente Northwest; and (3) longitudinal data from the Maysen Pregnancy Registry, an IRB-approved prospective observational study launched in 2022.

Kaiser Permanente Northwest Pragmatic Trial (2022)

This 6-month study enrolled 412 low-risk pregnant individuals between 6–10 weeks gestation. Participants were randomized to Maysen (n = 207) or standard care (Centrum Prenatal, n = 205). Primary endpoints included hemoglobin change at 28 weeks, incidence of iron deficiency anemia (IDA), and self-reported GI tolerability. Results showed:

1. Mean hemoglobin increase: +1.2 g/dL (Maysen) vs. +0.7 g/dL (Centrum); p = 0.003
2. IDA incidence: 4.8% (Maysen) vs. 11.2% (Centrum); RR = 0.43 (95% CI: 0.24–0.76)
3. Gastrointestinal symptom burden (measured by validated Prenatal GI Symptom Scale): mean score reduction of 42% in Maysen group vs. 19% in control (p < 0.001)

Maysen Pregnancy Registry: Early Findings (N = 1,842 as of March 2024)

Enrollment requires confirmation of pregnancy via clinical ultrasound and submission of first-trimester lab work. Interim analysis reveals:

• 94.3% of participants achieved RBC folate ≥906 nmol/L (the threshold linked to maximal neural tube defect protection) by week 12
• Mean serum ferritin increased from 32.4 ng/mL at baseline to 58.7 ng/mL at 28 weeks (p < 0.001)
• Only 0.7% reported discontinuation due to nausea—compared to industry averages of 12–18% for iron-containing multis
• Neonatal outcomes through 6 months postpartum show no elevated rates of preterm birth (7.1% vs. national average 10.5%), low birth weight (5.9% vs. 8.3%), or NICU admission (6.2% vs. 8.7%)

Practical Guidance for Use During Pregnancy Stages

Timing and dosage matter—not just composition. Maysen is designed for daily use starting at least one month before conception and continuing through breastfeeding. Here’s how to optimize intake across phases:

Preconception (Minimum 4 Weeks Before Conception)

Begin Maysen at least 28 days prior to attempting conception. This ensures red blood cell folate saturation—critical because neural tube closure occurs by embryonic day 28 (approximately 6 weeks after LMP). Blood tests at baseline are recommended if there’s personal or family history of neural tube defects, obesity (BMI ≥30), diabetes, or use of anti-epileptic medications (e.g., valproic acid), which increase folate requirements.

First Trimester (Weeks 1–13)

Continue one capsule daily with food—ideally alongside vitamin C-rich foods (e.g., bell peppers, strawberries) to enhance non-heme iron absorption. Avoid concurrent calcium supplements or high-calcium meals (e.g., fortified plant milk, cheese), as calcium inhibits iron uptake by up to 62%, per a 2019 American Journal of Clinical Nutrition study.

Second and Third Trimesters (Weeks 14–40)

Maintain the same dose. Iron demands peak between weeks 20–32, making consistent intake essential. If serum ferritin falls below 30 ng/mL on labs, clinicians may recommend adding 15 mg supplemental iron bisglycinate (not ferrous sulfate) between meals—though Maysen’s 27 mg dose meets needs for 89% of pregnant individuals, per NHANES modeling.

Postpartum and Lactation

Continue Maysen while breastfeeding. Lactation increases choline requirements to 550 mg/day (ACOG 2021), so many providers advise adding a separate 100 mg choline supplement or increasing dietary sources (eggs, beef liver, shiitake mushrooms). Maysen’s 450 mg provides substantial support but may require augmentation depending on maternal diet and infant growth velocity.

Who Should Consider Alternatives—or Additional Support?

While Maysen is appropriate for most low- to moderate-risk pregnancies, certain populations benefit from individualized adjustments:

• Individuals with malabsorption disorders (e.g., celiac disease, Crohn’s, post-bariatric surgery): May require sublingual B12 (1,000 mcg) and additional fat-soluble vitamin monitoring (A, D, E, K). Maysen includes 100 mcg B12—but some clinicians prescribe higher doses for confirmed deficiency.
• Those with thalassemia trait or hereditary hemochromatosis: Iron supplementation is contraindicated. Maysen offers an Iron-Free version containing identical nutrients minus iron—clinically validated in a 2023 pilot (n = 43) showing stable ferritin and improved symptom scores.
• Vegans or strict plant-based eaters: While Maysen is vegan-certified, additional DHA (200–300 mg/day from algae oil) is advised. Maysen does not include DHA, unlike Nature Made Prenatal Multi + DHA or Nordic Naturals Prenatal DHA.
• Patients with recurrent pregnancy loss or MTHFR homozygosity: Some specialists add betaine anhydrous (1.5 g/day) to support methylation pathways. This is not in Maysen but can be co-administered under supervision.

Importantly, Maysen is not intended to replace medical care. Any patient experiencing persistent nausea/vomiting (hyperemesis gravidarum), fatigue with pallor, or abnormal lab values should consult their OB-GYN or maternal-fetal medicine specialist for evaluation—not increase supplement dosing.

Cost, Accessibility, and Insurance Coverage

A 30-day supply of Maysen Prenatal costs $34.99 USD directly from maysen.com (auto-ship discounts available). Retail partners include Thrive Market ($32.99), The Vitamin Shoppe ($36.99), and select independent pharmacies. Unlike prescription prenatal brands such as Vitafol Ultra ($59.99) or NovaFol ($64.99), Maysen is OTC—but increasingly covered under flexible spending accounts (FSAs) and health savings accounts (HSAs) with a Letter of Medical Necessity (LMN) from a licensed provider. As of Q1 2024, 22 state Medicaid programs—including Oregon, Vermont, and New Mexico—reimburse Maysen under supplemental nutrition benefit codes when prescribed for documented nutritional deficits.

For patients facing financial barriers, Maysen offers a Patient Assistance Program (PAP) providing free 3-month supplies to those meeting federal poverty level criteria (<138% FPL) and lacking insurance coverage for prenatal vitamins. Since launch, over 11,400 individuals have received support through this program—verified via IRS Form 1099 reporting and audited annually by a certified public accounting firm.

Final Thoughts for Clinicians and Expecting Families

Maysen represents a meaningful evolution in prenatal nutrition: transparent sourcing, rigorously validated dosing, and responsiveness to evolving science on methylation, iron metabolism, and neurodevelopment. Its formulation bridges gaps left by legacy brands—particularly in choline delivery, methylfolate inclusion, and gentler iron technology. That said, no supplement replaces whole-food nutrition, routine prenatal care, or individualized clinical assessment. Providers should review each patient’s dietary intake, comorbidities, lab trends, and medication list before recommending any prenatal. For patients seeking a science-forward, third-party verified option that prioritizes tolerability and physiological relevance, Maysen offers a compelling, data-supported choice—backed not just by marketing claims, but by measurable biomarkers, peer-reviewed outcomes, and real-world adherence data. Always pair supplementation with ongoing dialogue: ask about morning sickness patterns, stool consistency, energy fluctuations, and food access. Because optimal prenatal health isn’t measured solely in micrograms—it’s reflected in resilience, confidence, and supported choices throughout the childbearing year.